CytoSorbents announced that Alexander D’Amico has resigned as the company’s Chief Financial Officer as part of a mutual termination and release agreement with the Company, effective August 28, 2023. As part of the agreement, CytoSorbents and D’Amico have agreed to terminate his employment agreement with the Company dated July 10, 2023 in its entirety, and have agreed to customary and mutual non-disparagement and release provisions, payment of specific accrued expenses, and no severance payments or vesting of equity. Kathleen Bloch will continue to serve as the company’s Interim Chief Financial Officer pursuant to the existing consulting agreement arrangement between the company and Bloch.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CTSO:
- CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
- CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
- CytoSorbents granted expanded ANVISA registration to treat shock with CytoSorb
- CytoSorbents reports Q2 EPS (14c), consensus (11c)
- CytoSorbents Reports Second Quarter 2023 Financial and Operational Results